R&D

October 1, 2026

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy Endpoints NewsRegeneron weight-loss drug halves muscle loss in…

MMedication

September 30, 2026

Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes Endpoints News‘Godzilla’ of weight-loss drugs could…

MMedication

Roche cans muscle-preserving obesity drug, hands it back to Chugai

September 28, 2026

Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with…

HHealthcare

How Lundbeck’s CEO aims to keep firm ‘punching above its weight’

August 21, 2026

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove…

EEconomy

China acknowledges ‘temperature gap’ between tech boom and traditional slump

August 3, 2026

A top theoretical journal of the Communist Party has acknowledged that a stark economic divide exists between China’s…

UUnited Kingdom

First UK-built Islander passes 75% completion at Bembridge, on schedule for delivery

June 8, 2026

Britten-Norman has confirmed that the first new Islander to be produced through its fully reshored UK production line…

AArtificial intelligence

Nokia launches AI networking lab to drive co-innovation with partners and accelerate next era of AI-native data center networking

May 21, 2026

AMD believes customer collaboration and an open ecosystem are fundamental to accelerating AI innovation. By co-developing solutions with…

UUnited Kingdom

ICC UK to convene European business leaders in London amid global trade uncertainty

April 21, 2026

The International Chamber of Commerce United Kingdom (ICC UK) will host senior business representatives from more than 25…

AArtificial intelligence

Why AI Is A Game-Changer For Creatives, And Why The Creative Industries Must Fight For Their Rights

March 1, 2026

AI is transforming the creative industries, and the debate around whether it helps or harms artists is missing…

MMental health

February 17, 2026

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsBREAKING: Second Positive Phase 3…

MMedication

February 9, 2026

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints NewsRoche unveils data behind BTK inhibitor’s phase 3…

BBusiness

February 5, 2026

GSK’s new CEO eyes more dealmaking, intense pipeline inspection Endpoints NewsGSK (FY Results): another step towards mid-term target Hargreaves LansdownGSK…

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy – Endpoints News

Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes – Endpoints News

Roche cans muscle-preserving obesity drug, hands it back to Chugai

How Lundbeck’s CEO aims to keep firm ‘punching above its weight’

China acknowledges ‘temperature gap’ between tech boom and traditional slump

First UK-built Islander passes 75% completion at Bembridge, on schedule for delivery

Nokia launches AI networking lab to drive co-innovation with partners and accelerate next era of AI-native data center networking

ICC UK to convene European business leaders in London amid global trade uncertainty

Why AI Is A Game-Changer For Creatives, And Why The Creative Industries Must Fight For Their Rights

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News

GSK’s new CEO eyes more dealmaking, intense pipeline inspection – Endpoints News